Anzeige
Mehr »
Freitag, 12.06.2026 - Börsentäglich über 12.000 News
Diese Aktie anschauen - Kurz vor Rallye?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
306 Leser
Artikel bewerten:
(2)

UK's leading longevity clinic Get A Drip appoints new Chief Medical Officer Dr Luke Pratsides

LONDON, June 12, 2026 /PRNewswire/ -- Get A Drip, one of the UK's largest providers of longevity health treatments, is strengthening its clinical leadership with the appointment of Dr Luke Pratsides as its new Chief Medical Officer.

Dr Pratsides joins Get A Drip at a crucial time, amidst a consumer shift prioritising longevity in wellbeing. In the last 12 months alone, global Google searches for longevity have tripled. Get A Drip reports that between 2023-2025 bookings for NAD+ - one of the most talked about longevity treatments - saw an increase of 772.4%. The rise of longevity wellness services only looks set to increase.

But Dr Pratsides notes it's important to realise that longevity is "not just increasing years of life, but increasing the years of healthy life." That distinction is key at Get A Drip, which provides the tools to empower people to adopt a proactive approach to health and wellbeing.

As consumers look towards the high street for answers, Dr Pratsides' appointment will help drive the future of longevity innovation. His clinical outlook is rooted in preventative medicine and shaped by years of lived healthcare experience in both the private sector and frontline NHS practice. Dr Pratsides formerly led the medical team at Numan where he built the company's GLP-1 and testosterone hormone therapy prescribing services and clinical governance structures.

"We are delighted to welcome Dr Luke Pratsides as our new Chief Medical Officer and are excited for what the future holds," says Richard Chambers, founder and CEO of Get A Drip.

"Healthcare is at a pivotal juncture. Treatments that were once seen as a luxury are now featured as part of everyday wellness routines. As technology evolves and science continues to support the benefits, we're seeing a step change in consumer behaviour. This is promising because ultimately, people are taking charge and living healthier for longer. Now, together with Dr Pratsides, we are looking towards the future, spearheading progressive, proactive longevity measures."

Dr Luke Pratsides adds: "As a longevity organisation, we are focused on reducing risk across four major areas: cancer, cardiovascular disease, metabolic disease and neurodegenerative conditions. We may not have all the answers, but we have powerful tools in modern preventative medicine to move the needle on cardiovascular disease, diabetes risk and hormonal health."

Get A Drip launched in 2017, after founder Richard Chambers ended up in an intensive care unit fighting for his life. Complications from Diabetes Type 1 required life-saving medical intervention. This is where IV nutrition therapy changed his life, inspiring a mission to make these tools accessible to all.

The first Get A Drip clinic opened in London's Shoreditch and offered a range of medical grade IV nutrition therapy. Fast-forward to 2026 and the clinic has expanded, specialising in proactive treatments across 30-plus locations.

Get A Drip offers the most comprehensive diagnostics and blood testing on the market, alongside an extensive range of IV nutrition therapy and vitamin injections. The brand's two London flagship clinics feature cutting-edge longevity technologies such as Cryotherapy Chamber, Red Light Therapy beds, Hyperbaric Oxygen Therapy, Infrared Sauna and Compression Therapy. Sustainable weight management programmes with the use of GLP-1 medications are also available alongside clinical support.

Under supervision of the clinic's expert medical teams, customers can access a fully personalised approach to longevity wellness that identifies potential issues before they become a problem. It's a proactive approach, providing clients with the best chance of combating potentially preventable conditions.

Research shows that most chronic conditions are preventable, and more than 80% could be avoided through the adoption of healthy lifestyle recommendations. This fact underpins the ethos of Get A Drip.

To find out more about Get A Drip visit www.getadrip.com.

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/uks-leading-longevity-clinic-get-a-drip-appoints-new-chief-medical-officer-dr-luke-pratsides-302798960.html

© 2026 PR Newswire
Software vor dem Comeback – diese 5 Aktien könnten durchstarten!
Während Halbleiter- und KI-Infrastrukturwerte von einem Hoch zum nächsten jagen, wurden viele Software-Aktien in den vergangenen Monaten regelrecht aus den Depots gedrängt. Die Angst vor Disruption hat Investoren zu einem radikalen Strategiewechsel veranlasst – mit der Folge, dass zahlreiche Qualitätsunternehmen heute auf Mehrjahrestiefs notieren.

Doch genau hier entsteht eine seltene Chance. Denn während die Bewertungen im Halbleitersektor inzwischen auf ambitionierten Niveaus liegen, ist der Bewertungsabschlag bei Software-Titeln so hoch wie seit Jahren nicht mehr. Gleichzeitig liefern viele Unternehmen weiterhin starke Wachstumszahlen und integrieren KI erfolgreich in ihre Geschäftsmodelle. Die Diskrepanz zwischen Kursentwicklung und operativer Stärke könnte sich schon bald auflösen.

Für Anleger bedeutet das: antizyklisch denken und gezielt zugreifen, bevor der Markt dreht. Denn erste technische Signale deuten darauf hin, dass sich die Trendwende bereits anbahnt.

In unserem aktuellen Spezialreport stellen wir fünf Software-Aktien vor, die besonders aussichtsreich positioniert sind – mit starker Marktstellung, attraktiver Bewertung und hohem Aufholpotenzial.

Jetzt den kostenlosen Report sichern – bevor der Software-Rebound Fahrt aufnimmt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.